Background
Narrative review of immunotherapy in unresectable stage III NSCLC after concurrent chemoradiation (CCRT). Standard of care = CCRT + 1-year adjuvant durvalumab per PACIFIC.
Interventions and follow up
Design: Narrative review of immunotherapy strategies (durvalumab consolidation per PACIFIC; emerging chemo-immunotherapy combinations) in unresectable stage III NSCLC.
Primary endpoint: Synthesis of trial evidence and emerging strategies
mFollow up: Not applicable
Primary endpoint: Synthesis of trial evidence and emerging strategies
mFollow up: Not applicable
Results
PACIFIC OS (reference): Adjuvant durvalumab improves 5-year OS by ~10% absolute vs placebo.
Long-term DFS: ~33% alive and disease-free at 5 years despite durvalumab addition.
Long-term DFS: ~33% alive and disease-free at 5 years despite durvalumab addition.
Adverse events
Pulmonary: Durvalumab pneumonitis grade ≥3 in 3–5%.
Immune-related: Autoimmune toxicity 20–30% any grade; manageable with corticosteroids/immunosuppression.
Immune-related: Autoimmune toxicity 20–30% any grade; manageable with corticosteroids/immunosuppression.
Conclusions
Adjuvant durvalumab is standard, but modest (~33%) long-term DFS indicates need for novel strategies: induction immunotherapy, combination agents, biomarker-driven selection, and ctDNA monitoring.
Key Limitations
Narrative (non-systematic) review without quantitative pooling; subject to selection and interpretation bias. Reflects the evidence landscape as of 2022 and predates several later phase 3 readouts. No formal risk-of-bias assessment of included trials.
Clinical Context
PACIFIC-based CCRT + 1-year durvalumab (FDA/EMA approved) remains the standard of care for unresectable stage III NSCLC and is endorsed by ESMO guidelines. The review frames the rationale for intensification strategies (e.g., consolidation combinations) still under investigation; subsequent trials such as CheckMate 73L have not displaced durvalumab consolidation.